Get the Stockscreener App
5.95
0.00%
0.00
After Hours:
5.97
0.02
+0.34%
Orchestra Biomed Holdings Inc stock is traded at $5.95, with a volume of 248.77K.
It is up +0.00% in the last 24 hours and up +11.01% over the past month.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
See More
Previous Close:
$5.95
Open:
$5.99
24h Volume:
248.77K
Relative Volume:
0.66
Market Cap:
$357.63M
Revenue:
$32.72M
Net Income/Loss:
$-54.64M
P/E Ratio:
-5.2762
EPS:
-1.1277
Net Cash Flow:
$-55.08M
1W Performance:
-2.14%
1M Performance:
+11.01%
6M Performance:
+30.20%
1Y Performance:
+144.86%
1-Day Range:
$5.86
$6.17
1-Week Range:
$5.75
$6.48
52-Week Range:
$2.38
$6.48
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
Name
Orchestra Biomed Holdings Inc
Sector
Industry
Phone
646-343-9298
Address
150 UNION SQUARE DRIVE, NEW HOPE
Compare OBIO vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
5.95 | 357.63M | 32.72M | -54.64M | -55.08M | -1.1277 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Initiated | TD Cowen | Buy |
| Aug-20-25 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-20-25 | Initiated | BTIG Research | Buy |
| Jan-02-25 | Initiated | Barclays | Overweight |
| Aug-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | B. Riley Securities | Buy |
| Jan-19-24 | Initiated | Jefferies | Buy |
| Feb-24-23 | Initiated | Piper Sandler | Overweight |
| Feb-07-23 | Initiated | Chardan Capital Markets | Buy |
View All
Orchestra Biomed Holdings Inc Stock (OBIO) Latest News
Orchestra BioMed Holdings, Inc. (OBIO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength? - Yahoo Finance
Orchestra BioMed Gets $6.1 Million From Vivasure Sale - mychesco.com
Liquidity Mapping Around (OBIO) Price Events - Stock Traders Daily
Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026 - GlobeNewswire
Exploring These 3 Undervalued Small Caps With Insider Buying Across Regions - simplywall.st
Orchestra BioMed Highlights Pivotal Cardiovascular Program Progress - TipRanks
OBIO Maintained by B. Riley Securities -- Price Target Raised to $11.00 - GuruFocus
Orchestra BioMed Holdings Is Maintained at Buy by B. Riley Securities - Moomoo
Orchestra BioMed receives $6.1m milestone from Vivasure deal - Investing.com
Orchestra BioMed receives $6.1m milestone from Vivasure deal By Investing.com - Investing.com UK
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics - GlobeNewswire
B. Riley Adjusts Orchestra BioMed Price Target to $11 From $10, Maintains Buy Rating - marketscreener.com
Orchestra BioMed Obtains $6.1 Million Milestone Payment From Haemonetics' Acquisition of Vivasure - Yahoo Finance
Orchestra BioMed (OBIO) withholds CEO shares for taxes - Stock Titan
This Copart Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday - Benzinga
BTIG upgrades Orchestra BioMed stock rating on trial progress By Investing.com - Investing.com South Africa
Orchestra Biomed Holdings Inc : Btig Raises t - Moomoo
Orchestra BioMed Shares Rise After BTIG Upgrade - marketscreener.com
Orchestra BioMed at Wells Fargo: partnership model in focus By Investing.com - Investing.com Canada
These Two Healthcare Stocks Hit Key Milestones Today – Why Is Wall Street Bullish On Them? - Yahoo Finance
Crude Oil Surges 6%; Macy’s Shares Fall After Q2 Results - Benzinga
Wealthfront, Orchestra Biomed, AeroVironment And Other Big Stocks Moving Higher On Thursday - Benzinga
This Meta Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
BTIG Upgrades Orchestra BioMed to Buy From Neutral, Price Target is $10 - marketscreener.com
BTIG upgrades Orchestra BioMed stock rating on trial progress - investing.com
Orchestra BioMed CEO David Hochman buys $47,900 in common stock By Investing.com - Investing.com Australia
Orchestra BioMed presents investor slide deck detailing AVIM and Virtue SAB programs, strategic partners and 2027 catalysts - TradingView
Orchestra BioMed CEO David Hochman buys $47,900 in common stock - Investing.com
Orchestra BioMed (OBIO) CEO buys more of his own stock - Stock Titan
Orchestra BioMed Grants 133,000 Options to New Hires - MyChesCo
Orchestra BioMed (OBIO) president sells 15,000 shares under trading plan - Stock Titan
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Insider plans to sell 15,000 Orchestra BioMed (OBIO) shares - Stock Titan
Orchestra BioMed (OBIO) CFO logs 3,076-share tax withholding - Stock Titan
Orchestra BioMed (NASDAQ: OBIO) exec cites tax share withholding and son's 2,000-share buy - Stock Titan
Orchestra BioMed (OBIO) officer sees shares withheld for RSU taxes - Stock Titan
Avoiding Lag: Real-Time Signals in (OBIO) Movement - Stock Traders Daily
Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference - GlobeNewswire
Insiders Buying Orchestra BioMed Holdings Might Wish They Invested More, Stock Gains 29% - Moomoo
Orchestra (OBIO) Q2 2026 Results: Profit Per Share Clears Its Benchmark for the Current Session; Investor Response: Shares Finish 19.92% Higher in Latest TradingInvestor Earnings Call - vinanet.vn
Orchestra (OBIO) Reported Results Review: EPS Prints Above Forecast for the Current Session; Price Action: Shares Close 19.92% Higher at the CloseProfit Recovery Report - vinanet.vn
Orchestra BioMed Loss Widens as Pivotal Trials Advance - MyChesCo
Orchestra Biomed Holdings Inc Stock (OBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):